Eli Lilly: CHMP Recommends Approval of Baricitinib in Atopic Dermatitis
September 18 2020 - 8:38AM
Dow Jones News
By Michael Dabaie
Eli Lilly & Co. and Incyte said the European Medicines
Agency's Committee for Medicinal Products for Human Use issued a
positive opinion for baricitinib for the treatment of adult
patients with moderate to severe atopic dermatitis who are
candidates for systemic therapy.
The opinion marks the first step toward European regulatory
approval for baricitinib, marketed as Olumiant, for patients with
atopic dermatitis.
The CHMP opinion is now being referred for action to the
European Commission, which grants approval in the European Union. A
final decision is expected from the European Commission in the next
one to two months, the companies said.
Olumiant is already approved in more than 70 countries as a
treatment for adults with moderately to severely active rheumatoid
arthritis. Lilly has exclusive worldwide development and
commercialization rights for baricitinib and some follow-on
compounds for patients with inflammatory and autoimmune diseases
under a license and collaboration agreement with Incyte.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
September 18, 2020 08:23 ET (12:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2023 to Apr 2024